细胞收获系统市场份额、大小的趋势, Industry Analysis Report By Techniques (Altered Nuclear Transfer, Blastomere Extraction); By Application (Umbilical Cord, Bone Marrow, Peripheral Blood, Adipose Tissue, Other Sources); By End User (Biotechnology & Biopharmaceutical Companies, Research Institutes, Hospitals, Clinics, Others); By Regions, Segment Forecast, 2020 - 2026

报告摘要

2019年，全球细胞采集系统市场价值为468580万美元，预计2020年至2026年的复合年增长率为13.9%。对再生医学和细胞研究的投资不断增加生物技术and biopharmaceutical sectors, and increasing the incidence of chronic and infectious diseases are the main factors for cell harvesting market growth. The increasing rate of transplantation and increasing demand for stem cell banking are also some of the variables that are accountable for increasing harvesting requirements globally. The new sources of stem cells, such as adipose tissue, umbilical cord, and embryonic stem cells, have enormous potential for cancer treatment and regenerative product development that drives studies connected with these sources.

Chronic diseases are anticipated to rise by 57 percent by 2020, according to the World Health Organization (WHO). Increased demand for healthcare systems has become a significant problem owing to chronic illnesses. The Center for Disease Control and Prevention (CDC) says that chronic illnesses were the major cause of death and disability in the United States in 2019 and that there was at least one chronic disease among 133 million Americans, i.e. approx. 45% of the population. Moreover, rising age-related and lifestyle-related chronic illnesses increase healthcare demand and expenditure. Due to urbanization, sedentary lifestyles, shifting diets, increasing rates of obesity, and extensive accessibility of tobacco products, cancer and heart disease are becoming the primary causes of death in emerging economies. The significant factor for market growth is the potential use of stem cells in the treatment of multiple chronic diseases. Increasing the incidence of chronic and infectious diseases is anticipated to stimulate the development of the industry.

了解有关此报告的更多信息：request for sample pages

由于血癌和贫血发病率的升高，骨髓移植过程的增加，细胞采集系统市场正在经历快速发展。此外，增加医疗保健支出、治疗后生存、增加后勤设施投资、扩大心脏骨髓移植登记以及神经疾病，并增加人均医疗保健支出。betway体育亚洲版入口

细胞采集是一种将干细胞与功能正常的干细胞收集起来，用于再生、移植或修复受损器官的方法。在生物制药制造业中，细胞收获被认为是一个重要的步骤，可以直接影响产品的质量和相关的下游程序。干细胞的获取可以治疗癌症、血液疾病、免疫缺陷疾病和多发性事故等疾病。这种治疗方法对烧伤患者也很有用，可以帮助他们润滑新鲜的皮肤细胞，作为受损皮肤细胞的替代品。许多企业专注于心肌组织的再生，通过细胞移植注射患者的成体干细胞来生产再生药物。

细胞采集机制可以减少穿刺次数，减少从髂骨抽取骨髓的侵袭性。它也有助于减少处理时间和T细胞污染。然而，细胞获取行业的一个重要障碍是：繁琐的治疗费用高、免疫排斥、缺乏补偿措施、成人组织中干细胞的鉴定、可行的细胞密度、细胞获取过程中的并发症以及移植的HSC细胞数量不足。

Cell Harvesting Systems Market Report Scope

The market is primarily segmented on the basis of type, application, end user and geographic region.

By Technique	按应用程序	按最终用户	按区域类型
改变的核移植 Blastomere Extraction	Umbilical cord 骨髓 外周血 Adipose tissue 其他来源	Biotechnology & Biopharmaceutical Companies 研究机构 医院 Clinics Others	北美（美国、加拿大） 欧洲（德国、英国、法国、意大利、西班牙） Asia Pacific (China, South Korea, Japan, India) 拉丁美洲（巴西、墨西哥、哥伦比亚） MEA (Saudi Arabia, South Africa, Israel, UAE)

了解有关此报告的更多信息：request for sample pages

应用程序概述

在预测期内，干细胞研究有望成为增长最快的应用领域。对人类干细胞的研究有助于理解基本的人类生物学。研究干细胞有助于研究人员更好地理解身体功能以及疾病如何生长和影响身体。对干细胞的研究有助于科学家更好地理解不同的疾病和环境，并找到新的治疗方法。人类干细胞研究应纳入生物医学研究的主流，包括细胞变性过程研究、疾病建模、毒理学和药物筛选平台开发、再生治疗等。根据国家卫生研究所发布的信息，全球每年约有6万名患者接受骨髓移植治疗。骨髓来源的干细胞可以促进干细胞生物学、干细胞治疗和再生医学的研究。因此，由于上述因素，预计市场在预测期内将经历较高的发展。

区域展望

It is estimated that North America holds a substantial share in the cell harvesting systems industry and is anticipated to demonstrate a similar trend over the forecast period without significant changes. Due to increased study spending and public projects, the U.S. industry dominates the cell harvesting industry. The only stem cell-based products currently approved by the FDA for use in the U.S. are blood-forming stem cells obtained from cord blood. These, as well as stem cells from the bone marrow, are frequently used to treat patients with cancer and blood and immune system illnesses in transplant processes. In addition, healthcare expenditure in the United States is rising. These factors are the key components that increase the market's development and make it stable in the U.S. However, in the U.S., a 2019 study discovered hundreds of hospitals in the U.S. selling unapproved stem cell medicines that are likely to hamper market development in the U.S., which is likely to hamper market development.

Competitive Landscape

The key players operating in the cell harvesting systems market include PerkinElmer Inc. Tomtec, Bertin Technologies, TERUMO BCT, INC., hynoDent AG, Avita Medical, Argos Technologies, Inc., SP Scienceware, Teleflex Incorporated., Arthrex, Inc., Thomas Scientific, BRAND GMBH. Growing investment in stem cell-based studies by public authorities and an increase in the aging population can be ascribed to the growing demand for these therapies in these nations. This in turn is providing the major players in the cell harvesting market to capitalize on the opportunities provided in the global market.